Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation: Complete Statistical AnalysisIndependent statistical analysis of Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01115166).
- Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy: Complete Statistical AnalysisIndependent statistical analysis of Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be…
- BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment: Complete Statistical AnalysisIndependent statistical analysis of BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment: primary endpoint results, effect estimate with…
- BMS 247550 to Treat Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of BMS 247550 to Treat Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00030992).
- BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00095173).
- BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC): Complete Statistical AnalysisIndependent statistical analysis of BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bmt4me 2Independent statistical analysis of BMT4me: Post-HSCT Medication Adherence mHealth App: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05515497).
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): Complete Statistical AnalysisIndependent statistical analysis of BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens: Complete Statistical AnalysisIndependent statistical analysis of Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Body Mind Training Project: Complete Statistical AnalysisIndependent statistical analysis of Body Mind Training Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01564394).
- Body Weight, Sleep, and Heart Health: Complete Statistical AnalysisIndependent statistical analysis of Body Weight, Sleep, and Heart Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03388788).
- BODY-REALIndependent statistical analysis of Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BOLD 113Independent statistical analysis of This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas: primary endpoint results,…
- BOLERO-3Independent statistical analysis of Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- BOLTIndependent statistical analysis of A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: Complete Statistical AnalysisIndependent statistical analysis of BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: Complete Statistical AnalysisIndependent statistical analysis of Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: primary endpoint results, effect estimate…
- Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.: Complete Statistical AnalysisIndependent statistical analysis of Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.: primary endpoint results, effect estimate with…
- Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting: Complete Statistical AnalysisIndependent statistical analysis of Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BOOST®Independent statistical analysis of Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine:…
- Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).
- BOOST™Independent statistical analysis of Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BOOST™Independent statistical analysis of Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BOREASIndependent statistical analysis of Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- Bosentan for Poorly Controlled Asthma: Complete Statistical AnalysisIndependent statistical analysis of Bosentan for Poorly Controlled Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00815347).
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- Botox + FESIndependent statistical analysis of Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Botox Cosmetic and the Young Patient With Glabellar Furrows: Complete Statistical AnalysisIndependent statistical analysis of Botox Cosmetic and the Young Patient With Glabellar Furrows: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00856999).
- BOTOX® Economic Spasticity Trial (BEST): Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Economic Spasticity Trial (BEST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549783).
- BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02230956).
- BOTOX® for the Treatment of Platysma Prominence: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® for the Treatment of Platysma Prominence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03915067).
- BOTOX® in the Treatment of Crow’s Feet Lines in Japan: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® in the Treatment of Crow's Feet Lines in Japan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01797081).
- BOTOX® Prophylaxis in Patients With Chronic Migraine: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Prophylaxis in Patients With Chronic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01432379).